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HEALTH CARE COSTS AND UTILIZATION FOR PRIVATELY INSURED PATIENTS
TREATED FOR NON-INFECTIOUS UVEITIS IN THE UNITED STATES
Johnson S1, Duh MS1, Mallya U2, Diener M3, Sorg R3, Chu D4
1Analysis Group, Inc., Boston, MA, USA, 2Novartis Pharmaceuticals Corporation, Florham Park ,
NJ, USA, 3Analysis Group, Inc., New York, NY, USA, 4UMDNJ, Newark, NJ, USA
OBJECTIVES:Describe costs and utilization patterns of corticosteroid (CTS), immu-
nosuppressive (IMS), and biologic (BIO) treatment use in patients with chronic
non-infectious uveitis. Costs and utilization of CTS, IMS and BIO indicate economic
burden but have not been studied in a large sample. METHODS: Patients with 31
NPSU diagnosis (ICD-9-CM 360.x–364.x, excluding infectious uveitis) by an ophthal-
mologist or 32 by a primary care physician, under age 65, with continuous insur-
ance coverage during a six-month baseline were selected from a privately insured
claims database (N80.7 million). Sample index dates were defined as the first
prescription/administration of CTS, IMS, or BIO between 2003-2009. CTS patients
had 32 10-day or 31 30-day scripts. Analysis was in a per-member-per-month
(PMPM) framework based on treatment episodes, defined as continuous medica-
tion usewithin the same class.Wilcoxon rank-sum and chi-square tests were used
for comparisons of costs and categorical outcomes. RESULTS: CTS (N19,426), IMS
(N5,466) and BIO (N1,694) samples were selected; average time on continuous
therapy (i.e., treatment episode duration) was 1.79, 3.66, and 8.18 months (p0.05
across groups). Baseline Charlson Comorbidity Index was highest for BIO (0.83),
then IMS (0.78), then CTS (0.039) (p0.05 across groups). Baseline PMPM inpatient
admission rates were 0.021 for CTS, 0.044 for IMS, and 0.045 for BIO (p0.05 across
groups); study period values were 0.032, 0.048, and 0.024, respectively (p0.05 CTS
different vs. both). Emergency room visits had a similar ordering. Baseline average
PMPM costs for CTS were $717; IMS were $1738; and BIO were $1439 (p0.05 across
groups). Study period PMPM costs excluding drug or biologic costs were $974 for
CTS; were $1592 for IMS; and were $918 for BIO (p0.05 across groups).
CONCLUSIONS: BIO had the best relative change in outcomes, followed by IMS.
There could be underuse of these products relative to CTS.
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PRODUCTIVITY LOSSES ASSOCIATED WITH VISION IMPAIRMENT IN CANADA
Lachaine J1, Beauchemin C1, Mathurin K1, Blouin J2
1University of Montreal, Montreal, QC, Canada, 2Novartis Pharmaceuticals Canada Inc., Dorval,
QC, Canada
OBJECTIVES: In Canada, visual impairment is highly prevalent and is associated
with a substantial socioeconomic impact on patients, and especially on caregivers.
The objective of this study was to explore the current evidence on productivity
losses associated with vision impairment, such as caregiver support, and to esti-
mate the cost of these productivity losses in Canada according to visual impair-
ment severity.METHODS: A literature search was conducted in MedLine and Em-
base databases using the keywords “visual acuity,” “vision loss,” “burden,” and
“cost.” Studies included in the search dated from January 2000 to June 2011. Data
were extracted from studies that reported productivity losses according to vision
impairment severity and in terms of duration of work lost. The mean number of
hours requiring help per year reported in the studies wasmultiplied by the average
Canadian hourly wage ($CAD22.85 in May 2011) to calculate the average costs as-
sociated with productivity losses. RESULTS: In all, 885 articles addressing the bur-
den of vision impairmentwere retrieved. Of these, two reported productivity losses
in terms of duration of work lost and according to the severity of vision impair-
ment. In both studies, visual impairment severity was categorized by levels of
visual acuity (VA). The duration of work lost increased with decreasing visual acu-
ity. On average, patients incurred annual productivity loss-related costs ranging
from $CAD347 to $CAD48,183 for VA scores ranging from 20/10 to worse than
20/320, respectively. CONCLUSIONS: Productivity losses and related costs associ-
ated with vision impairment are substantial, and they correlate with vision loss
severity. Caregiver-related costs are the largest component of productivity losses.
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ECONOMIC BURDEN OF WET AGE-RELATED MACULAR DEGENERATION
(WAMD) IN URBAN CHINA
Zhang YB1, Hu SL1, He JJ1, Wang D2
1Shanghai Health Development Research Center, Shanghai, China, 2Beijing Novartis Pharma Co.,
Ltd., Beijing, China
OBJECTIVES: This study aims to understand the direct and indirect cost of patients
with wAMD in urban China, and to assess the economic burden of wAMD in real
world from societal perspective. METHODS: A cross-sectional study was carried
out in 15 key eye centers and hospitals in 4 major cities of China (Beijing, Guang-
zhou, Shanghai and Chengdu) fromAugust 2010 through April 2011. Study subjects
were face-to-face interviewed by trained interviewers using structured question-
naires. Data of patients’ demographics, disease history, treatment pattern and
economic burden were collected based on medical charts and patient self-reports.
Utilities were calculated by regression formula under various measures, including
EQ-5D andNEI-VEF-25. Indirect cost was estimated by GDP per capitamultiplied by
DALYs and productivity weight. All cost were adjusted according to 2010 price
index in China. No discount was applied. RESULTS: Of the 417 eligible patients,
average agewas 67.93 (11.04) years old and 51.32%weremale. The averagewAMD
onset agewas 64.87(11.72) years old with average duration of 2.93 years. A total of
130 patients were bilateral, and a total of 547 wAMD eyes were identified. On
average, it costs 3,278 CNY per wAMD outpatient visit. Economic burden of wAMD
per eye per year was 29,640 CNY. Based on average life expectancy at 72 years old
from national statistics, economic burden of entire course of wAMD per eye was
estimated to be 207,450 CNY. Given the wAMD prevalence rate at 0.34% among
Chinese above 45 years old, the potential national burden of wAMD was 53.39
billionCNYper year, inwhich directmedical costwas 16.81 billionCNY, accounting
for 31.49%. CONCLUSIONS: In urban China, the economic burden for wAMD is
heavy both for patients and the society, while indirect cost account for majority
part of the burden.
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COST- EFFECTIVENESS OF RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR
WET AGE-RELATED MACULAR DEGENERATION (NAMD) AT THE MEXICAN
SOCIAL SECURITY SYSTEM (IMSS)
Arreola-Ornelas H1, Rosado-Buzzo A2, García-Mollinedo L2, Dorantes-Aguilar J2,
Lemus-Carmona E3
1OikoSalud and Fundación Mexicana para la Salud (FUNSALUD), Mexico City, Mexico, 2Links &
Links S.A, de C.V., Mexico City, Mexico, 3Novartis Pharmaceuticals Corporation, Mexico City,
Mexico
OBJECTIVES: To perform a cost-effectiveness analysis of Ranibizumab 0.5mg vs
Verteporfin photodynamic therapy (PDT) for the treatment of nAMD from the IMSS
perspective. METHODS: A Markov model was designed to analyze the disease in
patients 40 years-old. A systematic review was performed to obtain transition
probabilities used in the model. A hypothetical cohort was built from a retrospec-
tive database of patients with nAMD diagnosis at the IMSS*. The model identifies 4
states of changes in vision: Stability, Increase, Loss, Severe-Loss. Cycle duration
was 1 month, time horizon 5 years. Efficacy was evaluated by visual acuity gains
(VAG) of  15 letters; % of patient withdrawals due to adverse events (AEs) and
average utility score gain. Resource use of direct medical costs was identified from
expert review and valuated according to the Unitary Costs List published by the
IMSS. Sensitivity analysis was performed using a bootstrap technique. RESULTS:
Ranibizumab has the highest rate of patients with VAG 15 letters with 25.23%
versus 5.95% for Verteporfin PDT.Withdrawals due to AEs were 3.91% versus 5.05%
for Ranibizumab and Verteporfin PDT. Utilities were greater with Ranibizumab of
0.216 vs 0.143 for Verteporfin PDT. The total annual cost per treatment was higher
with Verteporfin PDT US$78,983.19 than Ranibizumab US$71,643.56. Ranibizumab
drug acquisition was US$124.6 lower than Verteporfin PDT. The costs were similar
between the two therapies in the Stability and Increase States; whereas in the Loss
and Severe-Loss, Ranibizumab had the lower cost for 29.8% and 16.6% less than
Verteporfin PDT. Sensitivity analysis showed absolute dominance and cost-effec-
tiveness of Ranibizumab in around 50% and 100% of the times, respectively.
CONCLUSIONS: For patients with nAMD, treatment with Ranibizumab is an effec-
tive and cost-saving option comparedwith Verteporfin PDT, allowing savings of up
to US$532 per patient-year which represents 9.3% of the total cost. Results are
consistent with previous analysis.
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ECONOMIC ANALYSIS OF ETANERCEPT AS PAUSED THERAPY IN MODERATE TO
SEVERE PSORIASIS FROM A PRIVATE PERSPECTIVE IN BRAZIL
Fernandes RA1, Takemoto MLS1, Amaral LM1, Cruz RB1, Mould JF2, Fujii RK3, Brandt H3,
Almeida GR3, Manfrin DF3
1ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 2Pfizer, Inc., New York, NY, USA,
3Pfizer, Inc., São Paulo, SP, Brazil
OBJECTIVES: Biologic treatment after systemic drugs fail in psoriasis is indicated
for obtaining clinical response. Etanercept effectiveness is not lost in retreatment
regimens, which allows continuous or paused therapeutic schemes. The inclusion
of etanercept in the private health care system practice represents a breakthrough
to psoriasis treatment in Brazil. This study aims to perform cost-effectiveness and
cost-utility analysis of biologic alternatives for moderate to severe psoriasis in
Brazil, from a private payer’s perspective. METHODS: A decision-tree model sim-
ulates psoriasis evolution after treatment with etanercept paused (50mg twice a
week for 12 weeks, followed by 25mg twice a week; 12-week treatment cycle and
12-week interruption), adalimumab (80mg at first week, followed by 40mg in the
second week, and then 40mg every two weeks) or infliximab (5mg/kg at weeks 0, 2
and 6 and then every 8weeks) and their associated costs in a 96-week time horizon.
Therapy continuation or switch was evaluated at week 24. Effectiveness measures
were PASI 75 success rate and quality adjusted life years (QALY) gained. Costs
included biologicals,medical follow-up and adverse eventsmanagement, collected
from Brazil private official databases (values represented 2010 USD). Probabilistic
sensitivity analyses were performed troughMonte Carlo simulation. A 5% discount
ratewas applied for costs and benefits.RESULTS: Effectiveness resulted in [PASI 75,
QALY] etanercept [51.3%, 1.5360], adalimumab [50.5%, 1.5339] and infliximab
[37.2%, 1.5001]. Treatment costs were 90,644USD, 110,663USD and 121,697USD, re-
spectively. Etanercept paused represented the least costly in all comparisons:
20,019USD and 31,054USD less than adalimumab and infliximab, respectively. Ac-
ceptability curves showed etanercept paused as the most cost-effective biologic.
CONCLUSIONS: In this analysis, etanercept presented the greatest effectiveness in
paused therapeutic scheme. Due to its lower costs, etanercept showed to be cost-
saving regarding PASI 75 success rate and QALY’s gained over other biologic treat-
ments in psoriasis management at Brazil private healthcare system.
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ECONOMIC ANALYSIS OF ETANERCEPT AS CONTINUOUS OR PAUSED THERAPY
IN MODERATE TO SEVERE PSORIASIS FROM A PUBLIC PERSPECTIVE IN
VENEZUELA
Fernandes RA1, Takemoto MLS1, Amaral LM1, Cruz RB1, Mould JF2, Rodriguez JC3
1ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 2Pfizer, Inc., New York, NY, USA,
3Pfizer, Inc., Caracas, Venezuela
OBJECTIVES: Biologic treatment after systemic drugs fail in psoriasis is indicated
for obtaining clinical response, what could avoid associated comorbidities. Regard-
ing biological drugs approved for psoriasis, etanercept effectiveness is not lost in
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retreatment regimens, which allows continuous or paused therapeutic schemes.
This study aims to perform cost-effectiveness and cost-utility analyses of biologic
alternatives for moderate to severe psoriasis in Venezuela, from a public payer=s
perspective.METHODS: A decision-tree model simulates psoriasis evolution after
treatment with etanercept continuous (50mg twice a week for 12 weeks, followed
by 25mg twice a week) or paused (12-week treatment cycle and 12-week interrup-
tion), adalimumab (80mg at first week, followed by 40mg in the second week, then
40mg every 2 weeks), infliximab (5 mg/kg at weeks 0, 2 and 6, then every 8 weeks)
or ustekinumab (45mg in weeks 0 and 4, then 45mg every 12 weeks) and their
associated costs in a 96-week time horizon. Therapy continuation or switch was
evaluated atweek 24. Effectivenessmeasureswere PASI 75 success rate and quality
adjusted life years (QALY) gained. Costs included biologicals, medical follow-up
and adverse events management, from Venezuela official databases (values repre-
sented 2010USD). Probabilistic sensitivity analyseswere performed throughMonte
Carlo simulation. A 5% discount rate was applied for costs and benefits. RESULTS:
Effectiveness resulted in [PASI 75, QALY]: etanercept [51.3%, 1.5360], adalimumab
[50.5%, 1.5339], infliximab [37.2%,1.5001] and ustekinumab [43.6%, 1.5164]. Treat-
ment costs [continuous, paused] were [16,741USD, 15,692USD], [17,846USD,
19,742USD], [35,685USD, 33,980USD] and [27,569USD, 26,922USD], respectively. Et-
anercept represented the least costly in all comparisons. Acceptability curves
showed etanercept in continuous and paused schemes as the most cost-effective
biologic. CONCLUSIONS: In this analysis, due to its lower costs and favorable ef-
fectiveness profile, etanercept showed to be cost-saving in both continuous and
paused treatment schemes regarding PASI 75 success rate and QALY’s gained.
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ECONOMIC ANALYSIS OF ETANERCEPT AS CONTINUOUS OR PAUSED THERAPY
IN MODERATE TO SEVERE PSORIASIS FROM A PUBLIC PERSPECTIVE IN
ARGENTINA
Fernandes RA1, Takemoto MLS1, Amaral LM1, Cruz RB1, Mould JF2
1ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 2Pfizer, Inc., New York, NY, USA
OBJECTIVES: Regarding biological drugs approved for psoriasis in Argentina, etan-
ercept effectiveness is not lost in retreatment regimens, which allows continuous
or paused therapeutic schemes. This study aims to perform cost-effectiveness and
cost-utility analyses of biologic alternatives for moderate to severe psoriasis in
Argentina, from a public payer’s perspective. METHODS: A decision-tree model
was used to simulate etanercept continuous (50mg twice a week for 12 weeks,
followed by 25mg twice a week) or paused (12-week cycle and 12-week interrup-
tion), adalimumab (80mg at first week, followed by 40mg in the second week, and
then 40mg every two weeks) or infliximab (5 mg/kg at weeks 0, 2 and 6 and then
every 8 weeks) in a 96-week time horizon. Therapy continuation or switch was
evaluated atweek 24. Effectivenessmeasureswere PASI 75 success rate and quality
adjusted life years (QALYs) gained. Costs included biologicals, medical follow-up
and adverse events management from Argentina official databases (values repre-
sented in 2010 USD). Probabilistic sensitivity analyses were performed through
Monte Carlo simulation. A 5% discount rate was applied for costs and benefits.
RESULTS: Effectiveness resulted in [PASI 75, QALY]: etanercept [51.3%, 1.5360],
adalimumab [50.5%, 1.5339] and infliximab [37.2%, 1.5001]. Treatment costs [con-
tinuous, paused] for etanercept, adalimumab and infliximab were [80,633USD,
60,056USD], [73,439USD, 74,362USD] and [112,274USD, 107,267USD], respectively. In
continuous scheme etanercept saved 31,641USD when compared to infliximab. In
paused scheme, etanercept represented the least costly treatment in all compari-
sons: 14,306USD and 47,211USD less than adalimumab and infliximab, respec-
tively. Acceptability curves showed etanercept paused as the most cost-effective
biologic. CONCLUSIONS: In this analysis, etanercept presented the greatest effec-
tiveness in continuous and paused therapeutic schemes. Due to its lower costs in
paused scheme scenario, etanercept showed to be cost-saving regarding PASI 75
success rate and QALY’s gained.
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ECONOMIC ANALYSIS OF ETANERCEPT AS PAUSED THERAPY IN MODERATE TO
SEVERE PSORIASIS FROM A PUBLIC PERSPECTIVE IN BRAZIL
Fernandes RA1, Takemoto MLS1, Amaral LM1, Cruz RB1, Mould JF2, Fujii RK3, Brandt H3,
Almeida GR3, Manfrin DF3
1ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 2Pfizer, Inc., New York, NY, USA,
3Pfizer, Inc., São Paulo, SP, Brazil
OBJECTIVES: Biologic treatment after systemic drugs fail in psoriasis is indicated
for obtaining clinical response, but not yet available in the Brazilian public health
care system. Etanercept effectiveness is not lost in retreatment regimens, which
allows continuous or paused therapeutic schemes. This study aims to perform
cost-effectiveness and cost-utility analysis of biologic alternatives for moderate to
severe psoriasis in Brazil, from a public payer’s perspective.METHODS:A decision-
tree model simulates psoriasis evolution after treatment with etanercept paused
(50mg twice a week for 12 weeks, followed by 25mg twice a week; 12-week treat-
ment cycle and 12-week interruption), adalimumab (80mg at first week, followed
by 40mg in the second week, and then 40mg every two weeks), infliximab (5mg/kg
at weeks 0, 2 and 6 and then every 8 weeks) or ustekinumab (45mg in weeks 0 and
4, then 45mg every 12 weeks) and their associated costs in a 96-week time horizon.
Therapy continuation or switch was evaluated at week 24. Effectiveness measures
were PASI 75 success rate and quality adjusted life years (QALY) gained. Costs
included biologicals,medical follow-up and adverse eventsmanagement, collected
from Brazil public official databases (values represented 2010 USD). Probabilistic
sensitivity analyses were performed troughMonte Carlo simulation. A 5% discount
ratewas applied for costs and benefits.RESULTS: Effectiveness resulted in [PASI 75,
QALY] etanercept [51.3%, 1.5360], adalimumab [50.5%, 1.5339], infliximab [37.2%,
1.5001] and ustekinumab [43.6%, 1.5164]. Treatment costs were 28,051USD,
35,001USD, 35,987USD and 40,183, respectively, and etanercept represented the
least costly in all comparisons: 6,951USD, 7,937USD and 12,132USD less than ada-
limumab, infliximab and ustekinumab, respectively. Acceptability curves showed
etanercept paused as themost cost-effective biologic. CONCLUSIONS: In this anal-
ysis, etanercept in paused therapeutic scheme presented the greatest effective-
ness. Due to its lower costs, etanercept showed to be cost-saving regarding PASI 75
success rate and QALY’s gained.
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ECONOMIC ANALYSIS OF ETANERCEPT AS CONTINUOUS OR PAUSED THERAPY
IN MODERATE TO SEVERE PSORIASIS FROM A PUBLIC PERSPECTIVE IN
COLOMBIA
Fernandes RA1, Takemoto MLS1, Amaral LM1, Cruz RB1, Mould JF2, Nuñez SM3,
Gutierrez-Ardila MV3
1ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil, 2Pfizer, Inc., New York, NY, USA,
3Pfizer Colombia, Bogota, Cundinamarca, Colombia
OBJECTIVES: Biologic treatment in psoriasis is indicated for obtaining clinical re-
sponse after systemic drugs fail. Among those approved in Colombia, etanercept
effectiveness is not lost in retreatment regimens, which allows continuous or
paused therapeutic schemes. This study aims to perform cost-effectiveness and
cost-utility analysis of biologic alternatives for moderate to severe psoriasis in
Colombia, from a public payer’s perspective. METHODS: A decision tree-model
simulates psoriasis evolution after treatment with etanercept continuous (50mg
twice a week for 12 weeks, followed by 25mg twice a week) or paused (12-week
treatment cycle and 12-week interruption), adalimumab (80mg at first week, fol-
lowed by 40mg in the second week, then 40mg every two weeks), infliximab
(5mg/kg at weeks 0, 2 and 6, then every 8 weeks) or ustekinumab (45mg in weeks 0
and 4, then 45mg every 12 weeks) and their associated costs in a 96-week time
horizon. Therapy continuation or switch was evaluated at week 24. Effectiveness
measures were PASI 75 success rate and quality adjusted life years (QALY) gained.
Costs included biologicals, medical follow-up and adverse events management,
collected from Colombia official databases (values represented 2010 USD). Proba-
bilistic sensitivity analyses were performed trough Monte Carlo simulation. A 5%
discount rate was applied for costs and benefits. RESULTS: Effectiveness resulted
in [PASI 75, QALY] etanercept [51.3%, 1.5360], adalimumab [50.5%, 1.5339], inflix-
imab [37.2%, 1.5001] and ustekinumab [43.6%, 1.5164]. Treatment costs [continu-
ous, paused] were [45,683USD, 35,420USD], [44,467USD, 45,123USD], [60,359USD,
58,335USD] and [42,818USD, 43,306USD], respectively. In continuous scheme etan-
ercept saved 14,678USD when compared to infliximab. In paused scheme, etaner-
cept represented the least costly in all comparisons. Acceptability curves showed
etanercept paused as themost cost-effective biologic. CONCLUSIONS: In this anal-
ysis, etanercept presented the greatest effectiveness in all therapeutic schemes.
Due to its lower costs in paused scenario, etanercept showed to be cost-saving
regarding PASI 75 success rate and QALY’s gained.
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SYSTEMATIC REVIEW OF COST-UTILITY ANALYSES IN AGE-RELATED
MACULAR DEGENERATION
Lin PJ1, Bliss S1, Fang CH2, Yeh WS3, Kowalski JW3, Neumann PJ1
1Tufts Medical Center, Boston, MA, USA, 2Pfizer, New Taipei City, Taiwan, 3Allergan, Inc.,
Irvine, CA, USA
OBJECTIVES: Age-related macular degeneration (AMD) is the primary cause of vi-
sion loss among older Americans and results in significant cost and reduced quality
of life. This study reviewed the methodology and results of published cost-utility
analyses (CUA) in AMD treatments. METHODS: We identified AMD-related CUAs
published from 2000 through 2010 using the Tufts Medical Center Cost-Effective-
ness Analysis Registry (www.cearegisty.org), which contains detailed information
onmore than 2,600 CUAs. In addition to the standard auditing process,we recorded
model structure, cost and effectiveness inputs, and assumptions employed in the
models. RESULTS:We identified 26 AMD-related CUAs containing 55 standardized
incremental cost-effectiveness ratios (ICERs, expressed as $US2010 per QALY) and
82 utility weights. The most common type of intervention was pharmaceuticals
(pegaptanib, ranibizumab, bevacizumab, vitamin therapy and/or antioxidants),
followed by medical procedures (laser photocoagulation, photodynamic therapy
with verteporfin). Approximately 55% of the reported ICERs were either dominant
(less expensive and more effective) or below $50,000 per QALY gained. Most of the
CUAs used Markov modeling over a lifetime horizon and estimated ICERs from
payer’s perspective. Vision acuity was typically modeled with static rather than
dynamic states. Most CUAs extrapolated effectiveness data beyond the timeframe
of clinical trials by using the “last-observation-carried forward” approach. Most
studies considered binocular AMD, but only considered the treatment, monitoring,
and utilityweight of the better-seeing eye. Key drivers of ICERs included the clinical
efficacy of treatment, utility weights, time horizon, and discount rate.
CONCLUSIONS: CUAs in AMD therapies suggest good value in many cases, but
great variations exist in the cost-effectiveness of AMD interventions, as well as
methods and assumptions employed in the CUA models. Few studies modeled
both the better-seeing and worse-seeing eyes among AMD patients. Future re-
search is needed to better understand the cost-effectiveness of treating bilateral
AMD based on longer-term data.
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